Cargando…

From simplicity to complexity in current melanoma models

Despite the recent impressive clinical success of immunotherapy against melanoma, development of primary and adaptive resistance against immune checkpoint inhibitors remains a major issue in a large number of treated patients. This highlights the need for melanoma models that replicate the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Michielon, Elisabetta, de Gruijl, Tanja D., Gibbs, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092692/
https://www.ncbi.nlm.nih.gov/pubmed/36103206
http://dx.doi.org/10.1111/exd.14675
_version_ 1785023408258416640
author Michielon, Elisabetta
de Gruijl, Tanja D.
Gibbs, Susan
author_facet Michielon, Elisabetta
de Gruijl, Tanja D.
Gibbs, Susan
author_sort Michielon, Elisabetta
collection PubMed
description Despite the recent impressive clinical success of immunotherapy against melanoma, development of primary and adaptive resistance against immune checkpoint inhibitors remains a major issue in a large number of treated patients. This highlights the need for melanoma models that replicate the tumor's intricate dynamics in the tumor microenvironment (TME) and associated immune suppression to study possible resistance mechanisms in order to improve current and test novel therapeutics. While two‐dimensional melanoma cell cultures have been widely used to perform functional genomics screens in a high‐throughput fashion, they are not suitable to answer more complex scientific questions. Melanoma models have also been established in a variety of experimental (humanized) animals. However, due to differences in physiology, such models do not fully represent human melanoma development. Therefore, fully human three‐dimensional in vitro models mimicking melanoma cell interactions with the TME are being developed to address this need for more physiologically relevant models. Such models include melanoma organoids, spheroids, and reconstructed human melanoma‐in‐skin cultures. Still, while major advances have been made to complement and replace animals, these in vitro systems have yet to fully recapitulate human tumor complexity. Lastly, technical advancements have been made in the organ‐on‐chip field to replicate functions and microstructures of in vivo human tissues and organs. This review summarizes advancements made in understanding and treating melanoma and specifically aims to discuss the progress made towards developing melanoma models, their applications, limitations, and the advances still needed to further facilitate the development of therapeutics.
format Online
Article
Text
id pubmed-10092692
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100926922023-04-13 From simplicity to complexity in current melanoma models Michielon, Elisabetta de Gruijl, Tanja D. Gibbs, Susan Exp Dermatol Review Articles Despite the recent impressive clinical success of immunotherapy against melanoma, development of primary and adaptive resistance against immune checkpoint inhibitors remains a major issue in a large number of treated patients. This highlights the need for melanoma models that replicate the tumor's intricate dynamics in the tumor microenvironment (TME) and associated immune suppression to study possible resistance mechanisms in order to improve current and test novel therapeutics. While two‐dimensional melanoma cell cultures have been widely used to perform functional genomics screens in a high‐throughput fashion, they are not suitable to answer more complex scientific questions. Melanoma models have also been established in a variety of experimental (humanized) animals. However, due to differences in physiology, such models do not fully represent human melanoma development. Therefore, fully human three‐dimensional in vitro models mimicking melanoma cell interactions with the TME are being developed to address this need for more physiologically relevant models. Such models include melanoma organoids, spheroids, and reconstructed human melanoma‐in‐skin cultures. Still, while major advances have been made to complement and replace animals, these in vitro systems have yet to fully recapitulate human tumor complexity. Lastly, technical advancements have been made in the organ‐on‐chip field to replicate functions and microstructures of in vivo human tissues and organs. This review summarizes advancements made in understanding and treating melanoma and specifically aims to discuss the progress made towards developing melanoma models, their applications, limitations, and the advances still needed to further facilitate the development of therapeutics. John Wiley and Sons Inc. 2022-10-05 2022-12 /pmc/articles/PMC10092692/ /pubmed/36103206 http://dx.doi.org/10.1111/exd.14675 Text en © 2022 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Michielon, Elisabetta
de Gruijl, Tanja D.
Gibbs, Susan
From simplicity to complexity in current melanoma models
title From simplicity to complexity in current melanoma models
title_full From simplicity to complexity in current melanoma models
title_fullStr From simplicity to complexity in current melanoma models
title_full_unstemmed From simplicity to complexity in current melanoma models
title_short From simplicity to complexity in current melanoma models
title_sort from simplicity to complexity in current melanoma models
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092692/
https://www.ncbi.nlm.nih.gov/pubmed/36103206
http://dx.doi.org/10.1111/exd.14675
work_keys_str_mv AT michielonelisabetta fromsimplicitytocomplexityincurrentmelanomamodels
AT degruijltanjad fromsimplicitytocomplexityincurrentmelanomamodels
AT gibbssusan fromsimplicitytocomplexityincurrentmelanomamodels